Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Sartorius AG
  6. News
  7. Summary
    SRT   DE0007165607


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sartorius Opens New Application and Service Hub in Zhangjiang Science City in Shanghai, China

09/16/2021 | 04:30am EDT

Sartorius officially opened its new, significantly expanded Application and Service Hub in Zhangjiang Science City in Shanghai, China. Equipped with the latest innovative instrumentation and offering cutting-edge professional expertise, this Hub covering over 3,000 square meters accommodates the Sartorius Application Center 3.0, the Confidence®Validation Services Laboratory 2.0 and APAC Service Hub. This combined facility is designed as an integrated solution platform to empower and accelerate progress in areas ranging from research to process development to production in the Chinese life sciences and biopharmaceutical industries. "The grand opening of the Application and Service Hub marks a further milestone in Sartorius' development in China and underlines its long-term commitment to this fast-growing market," said Sarah Wang, Head of Sales and Services in China. Given the fast growth of the Chinese biopharmaceutical industry over the past years, Sartorius has been continuously investing to broaden its footprint and expanding its capacity in China to meet the growing needs of local customers. The latest innovations in bioanalytic, continuous processing and digitalization are now going live in the upgraded Application Center 3.0, where the new Sartorius process solutions will be showcased and experienced as their first point of entry. More importantly, early stage monoclonal antibody (mAb) and virus-based therapies can be discovered, and their process applications can be custom developed, tested, and verified. With help of intelligent digital systems, process data could be monitored and controlled with remote SCADA system, and deviations can be reliably detected and analyzed in real time to drive the best possible outcomes. These systems combined with the power of local Sartorius expertise will enable customers to benefit from more efficient and productive process solutions for their specific products, lowering their investment outlay and significantly reducing the time to market. In life science research and the biopharma industry, it is important not only to speed up the entire process chain from drug discovery to commercial-scale production, but also to ensure that each process step is robust and safe as well as complies with applicable GMP and GLP regulatory requirements. With its capacity and capabilities expanded, the new Sartorius China Confidence®Validation Services Laboratory 2.0 will enable customers to overcome validation-related challenges. The Sartorius Hub's sterile filter validation facility will double its capacity by 2022 to meet increasing local demand. Extractables and Leachables (E&L) testing and virus clearance studies are the new local capabilities, helping to ensure regulatory compliance and safe implementation of single-use systems in biopharmaceutical production and reliable clearance processes to guarantee patient safety. The new Sartorius APAC Service Hub ensures professional after-sales continuity for equipment repair, maintenance, and calibration service. As it is crucial for production-scale equipment to function correctly in customers' bioprocesses and this usually entails significant investments, Sartorius has expanded its Service Hub to provide real-equipment-based training, not only for Sartorius engineers in Asia but also for its customers' engineers to prevent malfunctions before they happen and to extend the service life of Sartorius equipment. Professional service engineers and a complete range of spare parts on stock speed up calibration, repair and maintenance of smaller-scale instruments significantly. Sartorius is investing increasingly in local capacity expansion and customer-centric services. The newly opened Customer Interaction Center in Beijing for testing, validating, and adjusting equipment functionalities has successfully completed its first large-scale customer project. Moreover, the Sartorius Laboratory and Service Center in YETDA Biopark in Yantai, China, is under construction. As of the first half of 2022, this facility will provide timely, on-site support to customers and biotech startups in their drug discovery and early development phases. Sartorius currently employs more than 700 team members in China and is continuously expanding its local organization.

© S&P Capital IQ 2021
All news about SARTORIUS AG
10/21SARTORIUS VORZUEGE : Warburg Research remains its Buy rating
10/21SARTORIUS VORZUEGE : Receives a Buy rating from JP Morgan
10/20SARTORIUS : Conference Call 9M|2021 Presentation
10/20SARTORIUS VORZUEGE : Kepler Cheuvreux reiterates its Buy rating
10/20SARTORIUS VORZUEGE : Sell rating from UBS
10/20SARTORIUS VORZUEGE : Warburg Research remains its Buy rating
10/20SARTORIUS VORZUEGE : Gets a Neutral rating from Berenberg
10/20SARTORIUS VORZUEGE : JP Morgan reiterates its Buy rating
10/20SARTORIUS : grows dynamically and profitably – Substantial double-digit increases in..
10/20SARTORIUS' : Nine-Month Profit Soars Almost 93% On Strong Revenue Growth
More news
Analyst Recommendations on SARTORIUS AG
More recommendations
Sales 2021 3 386 M 3 942 M 3 942 M
Net income 2021 417 M 486 M 486 M
Net Debt 2021 1 861 M 2 167 M 2 167 M
P/E ratio 2021 98,0x
Yield 2021 0,23%
Capitalization 39 175 M 45 569 M 45 612 M
EV / Sales 2021 12,1x
EV / Sales 2022 10,8x
Nbr of Employees 12 952
Free-Float 49,0%
Duration : Period :
Sartorius AG Technical Analysis Chart | SRT | DE0007165607 | MarketScreener
Technical analysis trends SARTORIUS AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 583,00 €
Average target price 483,55 €
Spread / Average Target -17,1%
EPS Revisions
Managers and Directors
Joachim Kreuzburg Chief Executive Officer
Rainer Lehmann Chief Financial Officer
Lothar Kappich Chairman-Supervisory Board
Oscar-Werner Reif Head-Research & Development
Volker Niebel Head-Production, Procurement & Business Operations
Sector and Competitors
1st jan.Capi. (M$)
SARTORIUS AG68.99%45 569
BIOTAGE AB (PUBL)92.95%2 038
908 DEVICES INC.-39.05%960